DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Anupam Rama - 2 Rama - 2 Apellis - 1 Michael Bloom - 1 Filspari - 1 — CNBC's Michael Bloom - 1
Top related locs:
4Q Thursday's U.S
Top related orgs:
JPMorgan - 2 ~$ - 1 Travere Therapeutics - 1 U.S . Food - 1 Drug Administration - 1

Search resuls for: "Anupam Rama"


3 mentions found


☆ JPMorgan says controversial eye disease treatment can more than double this biopharma stock
  + stars: | 2023-10-06 | by ( Lisa Kailai Han | ) www.cnbc.com   time to read: +1 min
A controversial eye treatment from Apellis can lead to sharp returns for investors, according to JPMorgan. The bank upgraded the biopharmaceutical stock to overweight from neutral and raised its price target to $81 from $60. The drug aims to treat an eye disease called geographic atrophy, which, according to the Syfovre website, affects about 1 million people. APLS YTD mountain Apellis ytd chart Analyst Anupam Rama believes that Apellis' overall pipeline has only been strengthened by recent approvals of Syfovre. The analyst noted that some physicians who had initially paused treatment of Syfovre have already begun to return to prescribing the injection.
Persons: Anupam Rama, Apellis, Rama, Michael Bloom Organizations: JPMorgan, ~$ Locations: 4Q
☆ JPMorgan says this little-known biotech company could rally 66%
  + stars: | 2023-07-21 | by ( Hakyung Kim | Https | Www.Linkedin.Com In Hakyungkim | ) www.cnbc.com   time to read: +1 min
Rare diseases treatment developer Travere Therapeutics has the potential for meaningful long-term value, according to JPMorgan. Analyst Anupam Rama initiated coverage on Travere with an overweight rating Friday. The December 2024 price target of $26 implies shares surging 66% from Thursday's close. Earlier this year, Filspari received accelerated approval from the U.S. Food and Drug Administration. The company is also awaiting regulatory feedback for pegtibatinase , which is designed to treat classical homocystinuria, a rare genetic metabolic disorder.
Persons: Anupam Rama, Filspari, Rama, — CNBC's Michael Bloom Organizations: Travere Therapeutics, JPMorgan, U.S . Food, Drug Administration Locations: Thursday's, U.S
☆ This little-known pharma stock can rally more than 60% in 2023, JPMorgan says
  + stars: | 2023-01-03 | by ( Sarah Min | ) www.cnbc.com   time to read: +2 min
A promising treatment for acute leukemia makes Syndax Pharmaceuticals an attractive stock, JPMorgan said. Analyst Anupam Rama initiated coverage of Syndax with an overweight rating ahead of what could be significant new data on the company's cancer therapy called revumenib. Shares of Syndax outperformed last year, rising more than 16%. The analyst's price target of $41 means the biotech stock could see another 61% increase from Friday's closing price. Additionally, the analyst is anticipating further data on another treatment for chronic graft-versus-host disease (cGVHD) called axatilimab in mid-2023.
0 next >>
Total: 3